tbuckley/cabot-search huggingface dataset:
1482O A phase III study comparing methotrexate (M), adriamycin (A) and cisplatin (P) with MAP + ifosfamide (MAP + IF) for the treatment of osteosarcoma: JCOG0905
Authors: H. Hiraga, R. Machida, A. Kawai, Y. Matsumoto, T. Yonemoto, Y. Nishida, A. Nagano, K. Ae, S. Yoshida, K. Asanuma, J. Toguchida, D. Huruta, R. Nakayama, T. Akisue, T. Hiruma, T. Morii, K. Tanaka, T. Kataoka, H. Fukuda, T. Ozaki
Journal: Annals of Oncology (2022)
1645O Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial
Authors: J. Capdevila Castillon, M. Plana, B. Castelo, L. Iglesias, J. Hernando, R. Yaya Tur, N. Baste, A. Carmona-Bayonas, S. Ruiz, J. Trigo, I. Lorenzo-Lorenzo, E. Grande, D. Lorente, L. Ugidos, G. Marquina, A. García-Alvarez, M. Taberna, J. Villamayor, J. Molina-Cerrillo, T. Alonso-Gordoa
Journal: Annals of Oncology (2022)
1552O Chemotherapy-induced peripheral neuropathy (CIPN) prevention trial evaluating the efficacy of hand-cooling and compression in patients undergoing taxan-based (neo-)adjuvant chemotherapy for primary breast cancer: First results of the prospective, randomized POLAR trial
Authors: L. Michel, P. Romar, M. Feisst, D. Hamberger, D. Schwarz, E. Kurre, E. Klein, M.O. Breckwoldt, A. Priester, M. Weiler, K. Smetanay, C. Fremd, D. Jäger, M. Bendszus, F. Marmé, A. Schneeweiss
Journal: Annals of Oncology (2022)
1503P Prevalence and clinical characteristics of metastatic synovial sarcoma (mSS) patients with tumours expressing NY-ESO-1 antigen (NY+) and who are HLA-A*02:01, *02:05 or *02:06 allele positive (HLA+): Cohort study from the French sarcoma group
Authors: A. Dufresne, A. Meurgey, S. Chabaud, J. Bollard, M. Jean-Denis, L. Tonon, N. Gadot, C. Le Névé, J-Y. Blay, M. Woessner, E. Klohe, T. Thayaparan, K. Blouch, I. Eleftheriadou, M.J. Nathenson, S. Pokras
Journal: Annals of Oncology (2022)
1384P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2010 to 2019
Authors: D.J. George, R. Sandin, N. Agarwal, S.T. Tagawa, Z. Klaassen, R. Bitting, K. Ramaswamy, B. Emir, C. Bland, A. Hong, L. Shi, H. Yang, W. Gao, W. Song, S. Freedland
Journal: Annals of Oncology (2022)
1382P FDG-positive/PSMA-negative PET lesion prevalence in metastatic castration-resistant prostate cancer and its correlation with lines of systemic therapy: Results from the prospective 3TMPO imaging study
Authors: F. Pouliot, F. Saad, P. Richard, E. Rousseau, S. Probst, E. Levesque, V. Castonguay, N. Marcoux, None M. Lodde, D. Juneau, Z. Hamilou, J-B. Lattouf, F-A. Buteau, M. Pavic, J-F. Castilloux, B. Neveu, G. Bouvet, A. Tetu, B. Guérin, J-M. Beauregard
Journal: Annals of Oncology (2022)
444TiP Trial in progress: A phase Ib study of sotorasib, a selective KRAS G12C inhibitor, in combination with panitumumab and FOLFIRI in treatment naïve and previously treated metastatic colorectal cancer (CodeBreaK 101)
Authors: T. Masuishi, Y. Kuboki, M.G. Fakih, J.H. Strickler, M. Furqan, E.J. Kim, P. Cardona, Q. Tran, E. Chan, D.S. Hong
Journal: Annals of Oncology (2022)
1474P Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study)
Authors: C. Iglesias Gómez, V. Blanco Lorenzo, R. Garcia Dominguez, I. García Carbonero, E. Feliciangeli, S. Galvan Ruiz, A. Gómez de Liaño, B. Perez Valderrama, A. Rodriguez Sanchez, R. Sánchez-Escribano, C. Suarez Rodriguez, M. Lázaro Quintela, E. Gallardo Diaz, J. Guma I Padro, J. Puente, J.C. Villa Guzman, J. García Sanchez, M. Martinez Kareaga, M.D.C. Beato Zambrano, J. Molina-Cerrillo
Journal: Annals of Oncology (2022)
1747P Impact of prior chemotherapy (Chemo) on pembrolizumab (Pembro) response in urothelial cancer (UC): Exploratory analysis of the phase III KEYNOTE-045 study
Authors: R. De Wit, D.J. Vaughn, Y. Fradet, L. Fong, N.J. Vogelzang, M.A. Climent Duran, A. Necchi, D.P. Petrylak, W.R. Gerritsen, H.P. Gurney, D.I. Quinn, S. Culine, C.N. Sternberg, D.F. Bajorin, T.K. Choueiri, J. Xu, K. Imai, B. Homet Moreno, J. Bellmunt, J-L. Lee
Journal: Annals of Oncology (2022)
1539P Real-world (RW) outcomes of second-line (2L) small cell lung cancer (SCLC) patients treated with lurbinectedin
Authors: A. Estrin, X. Wang, A. Boccuti, P. Prince, N. Gautam, B. Rengarajan, W. Li, T. Lu, Y. Cao, N. Naveh, R. D'Agostino, R. Ben-Joseph, A.K. Ganti
Journal: Annals of Oncology (2022)
1541P Real-world data of atezolizumab plus carboplatin-etoposide for patients with extensive stage SCLC: The UK experience
Authors: L. Moliner, L. Woodhouse, S. Ahmed, S. Bhagani, P. Sevak, A. Vijay, N. Steele, H-L.J. Gray, S.D. Robinson, M. Davidson, M.E.R. O'Brien, S. Cox, C. Powell, T. Khalid, None T.R. Geldart, L. Hennah, T. Newsom-Davis, None A. Denton, F. Blackhall, R. Califano
Journal: Annals of Oncology (2022)
1637P Impact of immune-related adverse events (irAEs) and survival (OS) in a cohort of MPM patients (p) treated with immunotherapy (IT)
Authors: S.M. Cedres Perez, A. Valdivia, J.D. Assaf, P. Iranzo Gomez, A. Callejo, N. Pardo Aranda, A.F. Navarro Mendivil, A. Martinez-Marti, G. Molina, V. Navarro, J. Gonzalo, M. Soleda, J. Frigola, C. Carbonell, R. Amat, R. Dienstmann, E. Felip
Journal: Annals of Oncology (2022)
1663MO DAV132 prevents antibiotic-induced intestinal microbiota dysbiosis and maintains anti-PD-1 efficacy: A proof-of-concept in tumor-bearing mice transplanted with human feces
Authors: M. Messaoudene, N. Saint-Lu, F. Sablier-Gallis, S. Ferreira, C. Le Bescop, M. Ponce, C. Féger, A. Andremont, J. de Gunzburg, B. Routy
Journal: Annals of Oncology (2022)
1749P Association between immune-mediated adverse events (imAEs) and outcomes in metastatic urothelial cancer (mUC) treated with durvalumab (D) alone or in combination with tremelimumab (T) in the DANUBE study
Authors: O. Abdeljalil, C.E. Stecca, C. Lu, H. Zhang, E.T. Goluboff, S. Sridhar
Journal: Annals of Oncology (2022)
1736MO Pure or mixed basal/squamous tumours present decreased outcomes after neoadjuvant chemotherapy in the GETUG-AFU V05 VESPER trial
Authors: C.D.S. Groeneveld, V. Harter, S. Culine, C. Krucker, V. Dixon, A. de Reynies, C. Pfister, F. Radvanyi, Y. Allory
Journal: Annals of Oncology (2022)
1709P Cascade genetic testing utilized only in 31% of initial families with pathogenic variants in breast cancer genes
Authors: D. Ziogas, K. Agiannitopoulos, G. Pepe, K. Potska, G. Tsaousis, D. Apostolopoulou, N. Tsoulos, V. Venizelos, C. Markopoulos, R. Iosifidou, S. Karageorgopoulou, S. Giassas, I. Natsiopoulos, K. Papazisis, M. Vasilaki-Antonatou, A. Psyrri, A. Koumarianou, C. Papadimitriou, E. Papadopoulou, G. Nasioulas
Journal: Annals of Oncology (2022)
1478P Clearseq1-4 classifier in localized and metastatic clear-cell renal cell carcinoma (ccRCC)
Authors: L. Kinget, E. Roussel, A.T.L. Verbiest, D. Lambrechts, B. Boeckx, J. Zucman-Rossi, G. Couchy, S. Caruso, M. Baldewijns, L. De Wever, M. Albersen, B. Beuselinck
Journal: Annals of Oncology (2022)
1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial
Authors: A.J. Armstrong, F. Saad, A. Thiery-Vuillemin, M. Oya, N.D. Shore, N. Mehra, M. Ozguroglu, C. Gedye, O. Sartor, C.H. Poehlein, P. Qiu, Y-Z. Liu, L. Riva, L. Harrington, L. Barker, P.M.D. Del Rosario, A. Barnicle, N. Clarke
Journal: Annals of Oncology (2022)
1668P Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction
Authors: X. Chen, E.G. Sifakis, S. Robertson, S.Y. Neo, S-H. Jun, L. Tong, J. Lövrot, A. Tay, R. Hellgren, S. Margolin, J. Bergh, T. Foukakis, J. Lagergren, A. Lundqvist, R. Ma, J. Hartman
Journal: Annals of Oncology (2022)
1578P Scalp cooling system for prevention of chemotherapy induced alopecia: A single center one-year prospective observational study
Authors: V. Agarwala, C. MV, A. Daga, M. Basu, M. Ganguly, S. Kumar, K. Mandal, S. Chakraborty, D. Sunani, N. Choudhary, K. Basu, S. Das, S. Mallik
Journal: Annals of Oncology (2022)
1533P Atezolizumab (ATZ) plus carboplatin (Cb) and etoposide (eto) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC): Results from the interim analysis of MAURIS trial
Authors: E. Bria, M.C. Garassino, E. Del Signore, F. Morgillo, F. Spinnato, A. Morabito, M. Iero, A. Ardizzoni
Journal: Annals of Oncology (2022)
1667P Multiplexed spatial analysis by imaging mass cytometry to immunologically characterize checkpoint inhibitor colitis
Authors: M. van Eijs, J.J.M. ter Linde, M.J.D. Baars, M.M. Amini, M.M. Laclé, E.C. Brand, B. Oldenburg, Y. Vercoulen, K.P.M. Suijkerbuijk, F. van Wijk
Journal: Annals of Oncology (2022)
1582P Real-world management of immune-related adverse events in the community setting
Authors: D.B. Johnson, D. Bruno, M. Rioth, C. Zhang, J. Palaia, R. Pisupati, C. Bond, L.C. Rosenblatt, R.G. Broome, M. Teka, H. Kluger
Journal: Annals of Oncology (2022)
1590P Interest of preventive treatment with anticoagulant in older patients with cancer on venous thrombo-embolic events (ANTIGONE study): Design and baseline results
Authors: O. Hanon, E. Paillaud, A. Baudin, S. Chaoui, J. Canovas, L. Iratni, P. Lucas, H. Mabungu, M. Villebrun, C. Chambraud, F. Rollot-Trad, M. Bringuier, A. Broussier, N. Spiess, I. Elalamy, F. Canouï-Poitrine
Journal: Annals of Oncology (2022)
271P Eribulin (E) plus endocrine therapy (ET) in patients (pts) with HR[+]/HER2[-] metastatic breast cancer (mBC) after progression on previous ET: The REVERT study
Authors: A. Lopez Gonzalez, S. Del Barco Berron, I. Garau Llinas, M. Galan Gramaje, B. Castelo, A. Cortes Salgado, P. Sanchez-Rovira, A. Martinez Bueno, A. García, P. Gener, L. Mina, D. Alcalá, M. Sampayo-Cordero, J. Cortés, J.M. Perez Garcia, A. Llombart Cussac, E. Lopez Miranda
Journal: Annals of Oncology (2022)
274TiP Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+/HER2–) breast cancer: TROPION-Breast01
Authors: A. Bardia, K. Kalinsky, J. Tsurutani, E.P. Hamilton, S. Johnston, J. Sohn, K.H. Park, Y.H. Park, S-A. Im, K.S. Lee, D. Dastur, V. Haddad, S. Khan, B. Xu, B. Pistilli, H.S. Rugo
Journal: Annals of Oncology (2022)
1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)
Authors: M. Stellato, S. Buti, M. Maruzzo, M. Bersanelli, P. Ermacora, B.A. Maiorano, V. Prati, U.F.F. De Giorgi, F. Pierantoni, A. Malgeri, A. Mennitto, A. Cavo, M.G. Vitale, M. Santoni, C. Carella, G. Procopio, E. Verzoni, D. Santini
Journal: Annals of Oncology (2022)
1514P Anti-tumor effects of the novel KIT mutant inhibitor M4205 in gastrointestinal stromal tumor (GIST) xenograft models
Authors: L. De Sutter, A. Wozniak, J. Verreet, U. Vanleeuw, L. De Cock, N. Linde, C. Drechsler, C. Esdar, R. Sciot, P. Schoeffski
Journal: Annals of Oncology (2022)
1634P Patterns of disease recurrence in relation to the extent of lymph node sampling in patients with resected lung carcinoid: A population-based study
Authors: J. Derks, L. Moonen, L. Hillen, R.J. van Suylen, M. den Bakker, J. von der Thüsen, R. Damhuis, W.A. Buikhuisen, E. van den Broek, J. Maessen, L.P.W.M. Maat, P.E. van Schil, E-J. Speel, A-M.C. Dingemans
Journal: Annals of Oncology (2022)
1673P Exploring different strategies to incorporate germline analysis in tumor whole genome sequencing
Authors: R. Koster, L. Schipper, D. van Beek, M. Mendeville, K. Samsom, E.H. Rosenberg, F. Hogervorst, P. Roepman, G. Meijer, E.E. Voest, T. van Wezel, L. van der Kolk, K. Monkhorst
Journal: Annals of Oncology (2022)
1497P Safety and efficacy of [90Y]Y-FAPI-46 radioligand therapy in patients with advanced sarcomas and other cancer entities
Authors: R.W. Hamacher, K.M. Pabst, L. Kessler, P.F. Costa, J. Ferdinandus, M. Weber, M. Lippert, K. Lueckerath, N. Hirmas, K. Kostbade, I.A. Mavroeidi, M.H.H. Schuler, M. Ahrens, C. Rischpler, S. Bauer, K. Herrmann, J.T. Siveke, W.P. Fendler
Journal: Annals of Oncology (2022)
1571P Cancer-related neuropathic pain (CRNP) in Europe: Impact of cancer stage on diagnosis and treatment of patients
Authors: D. Dupoiron, S. Brill, C. Eeeltink, D. Bell, B. Barragán, G.M. Petersen, M. Eerdekens, D. Ryan, M. Rakuša
Journal: Annals of Oncology (2022)
1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC)
Authors: P. Martin Romano, G. Roubaud, P. Lavaud, M. Cabart, A. Pages, D. Vasseur, E. Colomba, S. Cousin, M. Toulmonde, T. Grellety, Z. Castel Ajgal, R. Chabanon, A. Parpaleix, G. Buzzatti, K. Fizazi, C.A. Gomez-Roca, A. Italiano, Y. Loriot, S. Postel-Vinay
Journal: Annals of Oncology (2022)
1599P Intrapericardial cisplatin as treatment for malignant pericardial effusion: 13-year experience at Hospital Clinic of Barcelona
Authors: F.J. Muñoz i Carrillo, P. Amorós, D.S. Pesantez Coronel, R. Reyes, T.D. Barreto Zambrano, G. Carrera Domenech, E. Cascos, P. Castro, S. Fernández-Méndez, M.C. Font Puig, L. González-Aguado, I. Monge, J. Padrosa, N. Reguart Aransay, A. Téllez, A. Tuca, M. Viladot, C. Zamora, J. Marco Hernández
Journal: Annals of Oncology (2022)
1714P Single-cell RNA sequencing and proteomic analysis reveals dedifferentiation-immunosuppression loop formed by malignant cell and macrophage in intrahepatic cholangiocarcinoma
Authors: Q. Li, C. Ye, Q. Jiang, R. Chen, W. Wu, F. Yan, X. Shuaishuai, X. Zhang, J. Ruan
Journal: Annals of Oncology (2022)
1693P Incidence of NTRK genes fusion in adult brain tumours: A prospective cohort of 140 patients with cerebral gliomas and brain metastases
Authors: P. Métellus, C. Camilla, E. Bialecki, N. Beaufils, C. Vellutini, E. Pellegrino, P. Tomasini, I. Nanni, L. Ouafik
Journal: Annals of Oncology (2022)
1564P Cancer-related fatigue in colorectal cancer patients at the time of diagnosis
Authors: A. Ruiz-Casado, F.F. Franco, M. Romero-Elias, C. Fiuxa, L. Gutiérrez Sanz, A. Alvarez-Bustos, A. Sanchez Ruiz, D. Garcia Gonzalez, D. Gonzalez-Cutre, H. Cebolla
Journal: Annals of Oncology (2022)
1560P Barriers, facilitators, and preferences to exercise interventions in patients with metastatic breast cancer: A qualitative study in four European countries
Authors: J. Depenbusch, M. Sweegers, N. Aaronson, Y. Wengström, M. Backman, J.I. Arraras, M. Schranz, B. Büchler, M. Lachowicz, A.M. May, K. Steindorf, M. Stuiver
Journal: Annals of Oncology (2022)
1530P Durvalumab (D) + platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN
Authors: N. Reinmuth, J.W. Goldman, Y. Chen, K. Hotta, G. Statsenko, M.J. Hochmair, M. Özgüroğlu, J.H. Ji, M.C. Garassino, A. Poltoratskiy, F. Verderame, L. Havel, I. Bondarenko, G. Losonczy, N.V. Conev, H. Mann, P. Chugh, T.B. Dalvi, L. Paz-Ares
Journal: Annals of Oncology (2022)
LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
Authors: S. Qin, L.S. Chan, S. Gu, Y. Bai, Z. Ren, X. Lin, Z. Chen, W. Jia, Y. Jin, Y. Guo, A.V. Sultanbaev, M. Pazgan-Simon, M. Pisetska, X. Liang, C. Chen, Z. Nie, L. Wang, A-L. Cheng, A. Kaseb, A. Vogel
Journal: Annals of Oncology (2022)
LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial
Authors: M. Allaf, S.E. Kim, L.C. Harshman, D.F. McDermott, V.A. Master, S. Signoretti, S. Cole, H. Moon, N. Adra, E.A. Singer, J. Gills, T.K. Choueiri, B. Leibovich, M.D. Michaelson, None B. shuch, P.N. Lara, D.Y.C. Heng, A. Kapoor, M.A. Carducci, N.B. Haas
Journal: Annals of Oncology (2022)
LBA17 Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)
Authors: L. Buisseret, D. Loirat, P.G. Aftimos, K. Punie, C. Maurer, V. Debien, A. Goncalves, F. Ghiringhelli, D. Taylor, F. Clatot, T.F.A. van den Mooter, J-M. Ferrero, H. Bonnefoi, J-L. Canon, F.P. Duhoux, F. Bazan, P. Kristanto, E. de Azambuja, M. Ignatiadis, M. Piccart
Journal: Annals of Oncology (2022)
LBA23 Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial
Authors: J. Taieb, O. Bouche, T. André, E. Barbier, P. Laurent-Puig, J. Bez, C. Toullec, C. Borg, V. Randrian, L. Evesque, S. Corbinais, B. Buecher, H. Perrier, F. Di Fiore, C. Gallois, C. Lepage, F. El Hajbi, D. Tougeron
Journal: Annals of Oncology (2022)
LBA45 Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)
Authors: R. Salazar, S. Tafuto, M. Krogh, A. Teule, R. Garcia-Carbonero, H.J. Klumpen, B. Cremer, I. Sevilla, B. Eriksson, E. Tabaksblat, J-P. Metges, N.S. Reed, J. Schrader, V. Navarro, V. Valentí, J. Hernando, A.M. Colao, L. Vestermark, C. Carnaghi, J. Capdevila
Journal: Annals of Oncology (2022)
1525TiP TORNADO: A randomized multicenter open-label phase II study evaluating retifanlimab in combination with neoadjuvant chemotherapy in patients with selected retroperitoneal sarcomas
Authors: S. Albert, A. Italiano, M. Toulmonde, S. Cousin, R. Bahleda, M. Brahmi, S. Watson, C. Auzanneau, N. Douiri, L. Poignie, B. Lortal, F. Le Loarer, C. Bellera
Journal: Annals of Oncology (2022)
1416P Associations between metformin and mortality risks in Asian diabetic patients with prostate cancer undergoing androgen deprivation therapy: A retrospective cohort study
Authors: Y.H.A. Lee, J.M.H. Hui, J.S.K. Chan, K. Liu, E.C. Dee, K. Ng, P. Tang, G. Tse, A.C.F. Ng
Journal: Annals of Oncology (2022)
1404P A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration resistant prostate cancer (mCRPC): Interim safety results
Authors: T. Jindal, H. Han, P.S. Deshmukh, I. De Kouchkovsky, D. Kwon, H.T. Borno, V.S. Koshkin, A. Desai, R. Bose, J. Chou, T. Friedlander, E.J. Small, A. Angelidakis, M.S. Johnson, S. Feng, A. Patnaik, L. Fong, J. Alumkal, R. Aggarwal
Journal: Annals of Oncology (2022)
1521P Comprehensive genomic profiling (CGP) of epithelioid hemangioendothelioma (EHE) and liver angiosarcomas (LAS)
Authors: A. Shreenivas, R. Kurzrock, H-Z. Chen, A. Clark, None K. Dougherty, N.A. Danziger, S. Chakrabarti, J. Charlson, J.S. Ross
Journal: Annals of Oncology (2022)
LBA3 Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial
Authors: J.B.A.G. Haanen, M. Rohaan, T.H. Borch, J.H. van den Berg, Ö. Met, M. Geukes Foppen, J. Stoltenborg Granhøj, B. Nuijen, C. Nijenhuis, J.H. Beijnen, I. Jedema, M. van Zon, I. Mansfield Noringriis, R. Kessels, S. Wilgenhof, H.V. van Thienen, F. Lalezari, A.C.J. van Akkooi, M. Donia, I-M. Svane
Journal: Annals of Oncology (2022)
Antenatal dexamethasone for improving preterm newborn outcomes in low-resource countries: a cost-effectiveness analysis of the WHO ACTION-I trial
Authors: Katherine E Eddy, Joshua P Vogel, Nick Scott, Dagnachew Fetene, Tom Tidhar, Olufemi T Oladapo, Gilda Piaggio, My Huong Nguyen, Fernando Althabe, Rajiv Bahl, Suman P N Rao, Ayesha De Costa, Suchita Gupta, Abdullah H. Baqui, Mohammod Shahidullah, Saleha Begum Chowdhury, Salahuddin Ahmed, Saima Sultana, Iffat Ara Jaben, Shivaprasad S Goudar, Sangappa M Dhaded, Yeshita V Pujar, Sunil S Vernekar, Saraswati Welling, Geetanjali M Katageri, Muttappa R Gudadinni, Saumya Nanda, Zahida Qureshi, Harriet Tunu Baraka, Alfred Osoti, George Gwako, John Kinuthia, Samuel Ojo, Adesina Olubukola Adeponle, Ayede Adejumoke Idowu, Ebunoluwa Aderonke Adejuyigbe, Oluwafemi Kuti, Bankole Peter Kuti, Francis Bola Akinkunmi, Weyinmi Emmanuel Kubeyinje, Hadijat Olaide Raji, Olusanya Abiodun, Anthony Dennis Isah, Shabina Ariff, Sajid Bashir Soofi, Lumaan Sheikh, Almas Aamir, Farrukh Raza
Journal: The Lancet Global Health (2022)
LBA40 Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma
Authors: C. Lebbe, G.V. Long, C. Robert, O. Hamid, V.G. Atkinson, A.N. Shoushtari, A. Daud, O.E. Bechter, D. Schadendorf, R.J. Sullivan, R. Dummer, J.J. Grob, N. Lewis, L. Fan, S. Basu, G. Caponigro, V.G. Cooke, A. Lau, R. Amaria
Journal: Annals of Oncology (2022)
1406P Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)
Authors: J. Lang, S.T. Tagawa, S. Slovin, H. Emamekhoo, D. Rathkopf, W. Abida, K. Autio, H. Xiao, A.M. Molina, J. Eickhoff, J.M. Sperger, S. Dehm, D.M. Nanus, C.E. Kyriakopoulos
Journal: Annals of Oncology (2022)
LBA33 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase II study
Authors: J. Bourhis, C. Le Tourneau, B. Calderon, L. Martin, C. Sire, Y. Pointreau, J-F. Ramee, A. Coutte, P. Boisselier, M-C. Kaminsky-Forrett, J-P. Delord, F. Clatot, X. Sun, J. Villa, N. Magne, O. Elicin, L. Damstrup, K. Gollmer, P. Crompton, Y. Tao
Journal: Annals of Oncology (2022)
LBA44 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
Authors: A. Bottomley, M. Kicinski, G.V. Long, M. Mandala, V.G. Atkinson, C.U. Blank, A.M. Haydon, S. Dalle, A. Khattak, M.S. Carlino, A. Meshcheryakov, S.K. Sandhu, S.S. Puig Sarda, C. Coens, S. Suciu, D. Grebennik, C. Krepler, P. Lorigan, C. Robert, A.M.M. Eggermont
Journal: Annals of Oncology (2022)
LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial
Authors: B. Xu, Q.Y. Zhang, P. Zhang, Z. Tong, T. Sun, W. Li, Q. Ouyang, X. Hu, Y. Cheng, M. Yan, Y. Teng, Y. Pan, X. Yan, Y. Wang, W. Xie, X. Zeng, S. Jiang, N. Bayaxi, X. Zhu
Journal: Annals of Oncology (2022)
1627TiP Impact of patient education on immune-related adverse events (irAEs) during immune checkpoint inhibitor (ICI)
Authors: V.A. Berger, C. Jubé, A. Forestier, C. Mitonneau, H. Humeau, S. Limouzin, M. Tiercin, L. Morlière, L. Geoffrois, M. Cabart, M. Bertholet, C. Llambrich-Molines, S. Breysse, S. Laghouati, N. Beaumont
Journal: Annals of Oncology (2022)
LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)
Authors: T.K. Choueiri, T.B. Powles, L. Albiges, M. Burotto, C. Szczylik, B. Zurawski, E. Yanez Riuz, M. Maruzzo, A. Suarez Zaizar, L.E. Fein, F.A. Barros Schutz, D.Y.C. Heng, F. Wang, F. Mataveli, Y-L. Chang, M. van Kooten Losio, C. Suarez Rodriguez, R.J. Motzer
Journal: Annals of Oncology (2022)
LBA69 Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase II LITESPARK-004 study
Authors: R. Srinivasan, O. Iliopoulos, W.K. Rathmell, V. Narayan, B.L. Maughan, S. Oudard, T. Else, J.K. Maranchie, S.J. Welsh, A.B. Bøndergaard Iversen, K. Chen, R.F. Perini, Y. Liu, W.M. Linehan, E. Jonasch
Journal: Annals of Oncology (2022)